Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Updated . What changed?
Aziyo Biologics, Inc is a medical devices business based in the US. Aziyo Biologics shares (AZYO) are listed on the NASDAQ and all prices are listed in US Dollars. Aziyo Biologics employs 156 staff and has a trailing 12-month revenue of around USD$42.3 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced investors
52-week range | USD$10.55 - USD$18 |
---|---|
50-day moving average | USD$15.5521 |
200-day moving average | USD$13.6096 |
Wall St. target price | USD$20 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | N/A |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$42.3 million |
---|---|
Gross profit TTM | USD$19.8 million |
Return on assets TTM | 0% |
Return on equity TTM | 0% |
Profit margin | -45.54% |
Book value | N/A |
Market capitalisation | USD$155.9 million |
TTM: trailing 12 months
There are currently 153,475 Aziyo Biologics shares held short by investors – that's known as Aziyo Biologics's "short interest". This figure is 2% down from 156,647 last month.
There are a few different ways that this level of interest in shorting Aziyo Biologics shares can be evaluated.
Aziyo Biologics's "short interest ratio" (SIR) is the quantity of Aziyo Biologics shares currently shorted divided by the average quantity of Aziyo Biologics shares traded daily (recently around 13185.137457045). Aziyo Biologics's SIR currently stands at 11.64. In other words for every 100,000 Aziyo Biologics shares traded daily on the market, roughly 11640 shares are currently held short.
To gain some more context, you can compare Aziyo Biologics's short interest ratio against those of similar companies.
However Aziyo Biologics's short interest can also be evaluated against the total number of Aziyo Biologics shares, or, against the total number of tradable Aziyo Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aziyo Biologics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Aziyo Biologics shares in existence, roughly 20 shares are currently held short) or 0.0514% of the tradable shares (for every 100,000 tradable Aziyo Biologics shares, roughly 51 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Aziyo Biologics.
Find out more about how you can short Aziyo Biologics stock.
We're not expecting Aziyo Biologics to pay a dividend over the next 12 months.
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo, a biological envelope that remodels into vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic devices; and ProxiCor, Tyke, and VasCure, which are a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors, and proteins for use in vascular and cardiac repair, and pericardial closure. The company also provides FiberCel, ViBone, and OsterGro V that are viable matrices designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated human cellular dermal matrix designed to meet a range of surgical needs. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was founded in 2015 and is headquartered in Silver Spring, Maryland. It has additional offices in Roswell, Georgia; and Richmond, California
Everything we know about the Reddit IPO, plus information on how to buy in.
Everything we know about the Hayward Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Alignment Healthcare Inc IPO, plus information on how to buy in.
Everything we know about the Olink Holding AB (publ) IPO, plus information on how to buy in.
Everything we know about the Procore IPO, plus information on how to buy in.
Everything we know about the Navios South American Logistics Inc IPO, plus information on how to buy in.
Everything we know about the Lava Therapeutics IPO, plus information on how to buy in.
Everything we know about the Pop Culture Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Bukalapak IPO, plus information on how to buy in.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.